Earnings Call · Q2 FY2023·2023-07-26

Q2 23EPS +1.54%·Rev n/aQ1 23EPS +1.64%·Rev n/aQ4 22EPS +4.92%·Rev n/aQ3 22EPS -1.61%·Rev n/a⚠ consensus missing

Edwards Lifesciences Corp EW

Mark Wilterding — Vice President, Investor Relations

Bernard Zovighian — Chief Executive Officer

Scott Ullem — Chief Financial Officer

Robbie Marcus — Analyst

Larry Wood — Group President, Transcatheter Aortic Valve Replacement (TAVR)

Daveen Chopra — Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (TMTT)

Matthew Taylor — Analyst

Vijay Kumar — Analyst

−9.8%1d on move date−9.1% vs SPY3d−10.4%5d−12.3%

Research tier

Behavioral profile computed for 8 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more EW calls or request research access.

More EW calls Browse calls Request research access